Depleting antilymphocyte, or antithymocyte antibodies, have long been an integral part of
induction regimens and continue today to be used in the management of patients at risk of
early rejection or those in whom the introduction of calcineurins or other immune
suppressants must be delayed. Registry data demonstrate that the most commonly used
depleting antibody, rabbit anti-human thymocyte globulin (rATG), is associated with
improved outcomes following renal transplantation in high-risk patients, particularly in …